Q1 EPS Estimates for Legend Biotech Reduced by William Blair

Legend Biotech Co. (NASDAQ:LEGN) – Analysts at William Blair lowered their Q1 2025 earnings estimates for Legend Biotech in a research report issued to clients and investors on Wednesday, March 12th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($0.40) for the quarter, down from their prior forecast of ($0.19). The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. William Blair also issued estimates for Legend Biotech’s Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.85) EPS, Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.16 EPS, Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.33 EPS and FY2026 earnings at $0.79 EPS.

Legend Biotech (NASDAQ:LEGN) last announced its quarterly earnings data on Tuesday, March 11th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.46. The business had revenue of $186.50 million for the quarter, compared to analysts’ expectations of $179.00 million. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%. The firm’s quarterly revenue was up 134.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.40) earnings per share.

A number of other analysts have also recently weighed in on LEGN. Royal Bank of Canada reaffirmed an “outperform” rating and set a $86.00 target price on shares of Legend Biotech in a research note on Monday, December 9th. HC Wainwright boosted their target price on shares of Legend Biotech from $73.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, March 12th. Morgan Stanley decreased their target price on shares of Legend Biotech from $82.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday. Guggenheim reaffirmed a “neutral” rating on shares of Legend Biotech in a research note on Wednesday, March 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $83.00 target price on shares of Legend Biotech in a research note on Monday, December 9th. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, Legend Biotech has an average rating of “Moderate Buy” and an average target price of $79.17.

Legend Biotech Stock Performance

NASDAQ LEGN opened at $37.94 on Monday. The firm’s fifty day moving average price is $35.75 and its two-hundred day moving average price is $40.61. The stock has a market cap of $6.93 billion, a PE ratio of -39.94 and a beta of 0.19. Legend Biotech has a fifty-two week low of $30.17 and a fifty-two week high of $65.45. The company has a debt-to-equity ratio of 0.27, a quick ratio of 4.90 and a current ratio of 4.98.

Hedge Funds Weigh In On Legend Biotech

Hedge funds and other institutional investors have recently bought and sold shares of the company. Signaturefd LLC lifted its holdings in Legend Biotech by 1,052.7% in the fourth quarter. Signaturefd LLC now owns 1,729 shares of the company’s stock valued at $56,000 after buying an additional 1,579 shares during the period. GF Fund Management CO. LTD. acquired a new position in Legend Biotech in the fourth quarter valued at $56,000. Shell Asset Management Co. lifted its holdings in Legend Biotech by 62.0% in the fourth quarter. Shell Asset Management Co. now owns 2,090 shares of the company’s stock valued at $68,000 after buying an additional 800 shares during the period. OFI Invest Asset Management acquired a new position in Legend Biotech in the fourth quarter valued at $77,000. Finally, Quadrant Capital Group LLC raised its holdings in shares of Legend Biotech by 4,296.6% during the fourth quarter. Quadrant Capital Group LLC now owns 3,825 shares of the company’s stock valued at $124,000 after purchasing an additional 3,738 shares during the period. Institutional investors and hedge funds own 70.89% of the company’s stock.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).